ORDER
REPRINTS
METHYLENEDIFLUOROCYCLOPROPANE ANALOGUES
331
Deprotection of 12a and 13a using BCl3 afforded target analogues 8a and 9a in 75
and 77% yield, respectively. In a similar fashion, alkylation-elimination procedure
of 11 with 2-amino-6-chloropurine gave compounds 12c, 13c and 14c. The product
of a simple alkylation, compound 15b, was also isolated. After deprotection of 12c
and 13c, analogues 8c and 9c were obtained. Hydrolysis (1) of 8c and 9c furnished
guanine analogues 8b and 9b. Structures of all new compounds were confirmed by
1H, 13C and 19F NMR, UV and mass spectra including nuclear Overhauser effect
(NOE) data for analogues 8a and 9a.
Kineticstudiesofcyclopropene-methylenecyclopropanerearangement(19,20)
withcompounds12c, 13cand14cunderbasecatalysis/1,5-diazabicyclo[4.3.0]non-
5-ene (DBN), acetonitrile, room temperature/ by HPLC have provided a strong
evidence that composition of the products of alkylation-elimination procedure is
thermodynamically controlled.
Compound 8a inhibited the replication of human cytomegalovirus
(HCMV) in human foreskin fibroblast (HFF) culture with EC50 21 µM and it was
non-cytotoxic (IC50 > 100µM) in HFF and KB cells. Against HSV-1 in BSC-1 cells
(ELISA assay), EC50 was 70 µM. Interestingly, it was less potent than synadenol
(1) (1, B = adenine) but more effective than the corresponding saturated difluorocy-
clopropane analogue (21). Compounds 8b, 9a and 9b were without effect (EC50
>
100 µM). None of the analogues was effective against HIV-1. Other antiviral tests
are being continued.
ACKNOWLEDGMENTS
This work was supported by grants RO1-CA32779 (J. Z.) from the National
Cancer Institute and U19-AI31718 (J. C. D.) from the National Institute of Allergy
and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
REFERENCES
1. Qiu, Y.-L.; Ksebati, M. B.; Ptak, R. G.; Fan, B. Y.; Breitenbach, J. M.; Lin, J.-S.;
Cheng, Y.-C.; Kern, E. R.; Drach, J. C.; Zemlicka, J. J. Med. Chem. 1998, 41, 10–23.
2. Qiu, Y.-L.; Zemlicka, J. Angew. Chem. Int. Ed. 1998, 37, 1440–1441.
3. Qiu, Y.-L.; Ptak, R. G.; Breitenbach, J. M.; Lin, J.-S.; Cheng, Y.-C.; Kern, E. R.; Drach,
J. C.; Zemlicka, J. Antiviral Chem. Chemother. 1998, 9, 341–352.
4. Qiu, Y.-L.; Zemlicka, J. Synthesis 1998, 1447–1452.
5. Qiu, Y.-L.; Hempel, A.; Camerman, N.; Camerman, A.; Geiser, F.; Ptak, R. G.;
Breitenbach, J. M.; Kira, T.; Ling, L.; Gullen, E.; Cheng, Y.-C.; Drach, J. C.; Zemlicka,
J. J. Med. Chem. 1998, 41, 5257–5264.
6. Qiu, Y.-L.; Ptak, R. G.; Breitenbach, J. M.; Lin, J.-S.; Cheng, Y.-C.; Drach, J. C.; Kern,
E. R.; Zemlicka, J. Antiviral Res. 1999, 43, 37–53.
7. Rybak, R. J.; Zemlicka, J.; Qiu, Y.-L.; Hartline, C. B.; Kern, E. R. Antiviral Res. 1999,
43, 175–188.